DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / NGN Capital LLC
NGN Capital LLC
both early and growth/opportunity families, reported GAV $125M
Importance
26
moderate
Active deployment
0
low
Emerging
0
low
Completeness
50
elevated
Freshness
100
high
Research priority
7
low
Identity and regulatory footprint
- Headquarters
- Stamford, CTadviserinfo.sec.gov
- Office address
- 60 LONG RIDGE ROAD, SUITE 402, Stamford, CT, 06902adviserinfo.sec.gov
- Business phone
- 212-972-0077adviserinfo.sec.gov
- Website
- HTTP://NGNCAPITAL.COM
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 19, 2026
- Private funds reported
- 2 (2 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $113Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- mcavalieri@ngncapital.comngncapital.compublished by the subject
- business phone
- 212-972-0077adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
no observed deals yet
Stated (the firm’s website)
- Sectors
- not stated or not yet read
- Stages
- not stated or not yet read
- Geography
- new york, united states
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors: no observed deals yet
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
2 reported, 7 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| NGN Biomed 2a | Opportunity fund | 2007 form d first sale | Harvest | $99.2M Mar 15, 2024 | 86 | $173M of $350M | Mar 11, 2010 |
| NGN Biomed 2b | Fund | unknown | Unknown | $26.1M Mar 15, 2024 | 8 | unknown | unknown |
| NGN Optiscan Fund II, LP | Fund | 2020 adv first reported | Wound down | $1.8M Mar 30, 2020 | 25 | unknown | unknown |
| NGN Optiscan Fund III, LP | Fund | 2020 adv first reported | Wound down | $999,981 Mar 30, 2020 | 22 | unknown | unknown |
| NGN Optiscan Fund I, LP | Fund | 2019 adv first reported | Wound down | $2.3M Mar 30, 2020 | 14 | unknown | unknown |
| NGN Biomed Opportunity Annex Fund LP | Continuation vehicle | 2014 adv first reported | Wound down | $184,501 Mar 18, 2021 | 25 | unknown | unknown |
| NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg | Continuation vehicle | 2014 adv first reported | Wound down | $126,485 Mar 18, 2021 | 5 | unknown | unknown |
| NGN Biomed 1b | Fund | unknown | Wound down | $43,504 Mar 20, 2023 | 8 | unknown | unknown |
| NGN Biomed 1a | Fund | unknown | Wound down | $0 Mar 24, 2022 | 95 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
6 current, 1 departed
John R. Costantino
Managing partnerManaging General Partner
Kenneth S. Abramowitz
Managing partnerManaging General Partner
Peter Johann
Managing partnerManaging General Partner
John Richard Costantino
PartnerManager · since Jan 1, 2006
Kenneth Samuel Abramowitz
PartnerManager · since Apr 1, 2004
Peter Johann
PartnerManager · since Jan 1, 2006
1 departed (kept with end dates)
- Georg Nebgen · Manager · Apr 1, 2004 to Apr 25, 2014 Inference
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
19 dated events
- Sep 15, 2026NGN Capital LLC: INSTITUTIONAL_VC -> MULTI_STAGE_VC (both early and growth/opportunity families, reported GAV $125M)Classification changedClassificationInferenceno URL
- Mar 15, 2024NGN Biomed 1b no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Biomed 1bSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 20, 2023NGN Biomed 1a no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Biomed 1aSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 24, 2022NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg no longer reported on Form ADV by NGN Capital LLC
- Mar 24, 2022NGN Biomed Opportunity Annex Fund LP no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Biomed Opportunity Annex Fund LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 18, 2021NGN Optiscan Fund I, LP no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Optiscan Fund I, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 18, 2021NGN Optiscan Fund II, LP no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Optiscan Fund II, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 18, 2021NGN Optiscan Fund III, LP no longer reported on Form ADV by NGN Capital LLCFund no longer reportedFundsInferenceNGN Optiscan Fund III, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2020NGN Optiscan Fund III, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $999,981Fund first reported on Form ADVFundsFactNGN Optiscan Fund III, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2020NGN Optiscan Fund II, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $1,776,623Fund first reported on Form ADVFundsFactNGN Optiscan Fund II, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 18, 2019NGN Optiscan Fund I, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $2,273,290Fund first reported on Form ADVFundsFactNGN Optiscan Fund I, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 25, 2014Georg Nebgen (Manager) no longer on Schedule A of NGN Capital LLC
- Apr 25, 2014NGN Biomed Opportunity Annex Fund LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $18,600,000Fund first reported on Form ADVFundsFactNGN Biomed Opportunity Annex Fund LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 25, 2014NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $14,100,000
- Mar 30, 2012NGN Biomed 1a first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $49,700,000Fund first reported on Form ADVFundsFactNGN Biomed 1aSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012NGN Capital LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012NGN Biomed 1b first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $35,900,000Fund first reported on Form ADVFundsFactNGN Biomed 1bSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012NGN Biomed 2a first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $142,200,000Fund first reported on Form ADVFundsFactNGN Biomed 2aSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2012NGN Biomed 2b first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $40,350,000Fund first reported on Form ADVFundsFactNGN Biomed 2bSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 15, 2026Multi-stage venture firm (confirmed, 95%, cls-1)both early and growth/opportunity families, reported GAV $125M
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $125M across 2 vehicles
Evidence
47 observations from 3 sources